Log in with your email address username.


[Correspondence] Hepatitis C: the path towards effective universal therapy

The worldwide burden of hepatitis C virus (HCV) infection is a major public health concern. New direct antiviral agents (DAAs) have revolutionised the management of HCV infection, with eradication rates higher than 90%. However, their high cost has precluded their widespread use, leading to restrictive conditions of prescription in many countries. DAAs have been available to all people living in France who are infected with HIV for 2 years (first via temporary authorisation and then via marketing authorisations) regardless of their liver fibrosis stage.